SCM
VTGN icon

Sitrin Capital Management’s VistaGen Therapeutics VTGN Stock Holding History

Sitrin Capital Management’s Portfolio VTGN Stock Details VTGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-1,478
Closed -$23K – 39
2020
Q2 		$23K Buy
+1,478
New +$20.2K 0.01% 32

Other funds holding VTGN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
DADC
D.A. Davidson & Co Great Falls, Montana $16.5B AUM 19.94% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Carson Wealth (CWM LLC)
Carson Wealth (CWM LLC) Omaha, Nebraska $38.1B AUM 19.66% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Sitrin Capital Management's VTGN Position: Q3 2020 in Review

Sitrin Capital Management sold out of VistaGen Therapeutics (VTGN) in Q3 2020, closing a stake of 1,478 shares — an estimated $23K sold.

Sitrin Capital Management first reported a position in VTGN in Q2 2020 and held it in 1 quarter. The position peaked at $23K in Q2 2020. 28 funds tracked by Wall St. Rank hold VTGN as of Q3 2020.

  • Sitrin Capital Management reported no remaining VistaGen Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Sitrin Capital Management sold 1,478 VistaGen Therapeutics shares in Q3 2020, an estimated $23K.
  • Sitrin Capital Management first reported a position in VistaGen Therapeutics in Q2 2020 and held it in 1 quarter.
  • Sitrin Capital Management's VistaGen Therapeutics position peaked at $23K in Q2 2020.
  • 28 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q3 2020.

Based on Sitrin Capital Management's 13F filing for Q3 2020, filed 23 Oct 2020.